Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 833-841

  Seki, R ^a   Ohshima, K ^a   Fujisaki, T ^b   Uike, N ^c   Kawano, F ^d   Gondo, H ^e   Makino, S ^f   Eto, T ^g   Moriuchi, Y ^h   Taguchi, F ⁱ   Kamimura, T ^j   Tsuda, H ^k   Shimoda, K ^l   Okamura, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e Saga Prefectural Hospital   (Japan)

^f MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^g HAMANOMACHI HOSPITAL   (Japan)

^h Sasebo Shiritsu Sogo Hospital   (Japan)

ⁱ ASO IIZUKA HOSPITAL   (Japan)

^j HARASANSHIN HOSPITAL   (Japan)

^k KUMAMOTO CITY HOSPITAL   (Japan)

^l UNIVERSITY OF MIYAZAKI   (Japan)

more..

Author keywords

Cell cycle; DLBCL; P27; Prognostic factor; Rituximab; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; S PHASE KINASE ASSOCIATED PROTEIN 2; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 77950916977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp481     Document Type: Article

References (29)

1. . The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
2. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
3. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
4. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
5. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995-1007.
6. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
7. Sheaff RJ, Groudine M, Gordon M et al. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464-1478.
8. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
9. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199.
10. Latres E, Chiarle R, Schulman BA et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 2001; 98: 2515-2520.
11. Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069-2081.
12. Seki R, Okamura T, Koga H et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003; 73: 230-235.
13. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
14. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (CHOP-R) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
15. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
16. Jaffe ES, Harris NL, Stein H et al. (eds): Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001.
17. Lim MS, Adamson A, Lin Z et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002; 100: 2950-2956.
18. Guo Y, Karube K, Kawano R et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005; 19: 1058-1063.
19. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 74: 187-220
20. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-4213.
21. Udin S, Hussain A, Ahmed M et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol 2008; 216: 483-494.
22. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
23. Seki R, Ohshima K, Fujisaki T et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009; 100: 1842-1847.
24. Kudo Y, Kitajima S, Sato S et al. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61: 7044-7047.
25. Ganoth D, Bornstein G, Ko TK et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001; 3: 321-324.
26. Inui N, Kitagawa K, Miwa S et al. High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun 2003; 303: 978-984.
27. Hara T, Kamura T, Nakayama K et al. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276: 48937-48943.
28. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398: 160-165.
29. von der Lehr N, Johansson S, Wu S et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-1200.